MiR-101 could also inhibit the proliferation of liver cancer cells by targeting zinc finger protein 217 (ZNF217), mitogen-activated protein kinases (MAPK)/extracellular signal-regulated kinase (ERK) signaling pathways, and hepatocyte growth factor (HGF)/c-MET axis [22,23,24]. The gene discussed is ZNF217; the disease is liver cancer.